The nootropic peptide category is dominated by compounds that emerged from Soviet-era and post-Soviet Russian pharmacology and are largely unfamiliar to Western neuroscience and clinical practice. Semax and its fragments, Selank, Cerebrolysin, and a handful of related compounds are approved or widely prescribed in Russia and several Eastern European countries but have no FDA approval, limited Western clinical trial data, and circulate in the US and EU primarily through research-chemical channels.
Dihexa is the exception — a US-developed hexapeptide modeled on angiotensin IV that acts as a hepatocyte growth factor (HGF) mimetic, studied at Washington State University in Alzheimer's-disease models. Despite promising preclinical work, dihexa has not completed human trials and is sold only as a research chemical.
This guide covers four peptide families commonly grouped as nootropics: the Semax lineage (native Semax is a 7-amino-acid fragment of ACTH 4-10; Semax 4-7 is a further heptapeptide fragment; N-acetyl-Semax and N-acetyl-Semax-amidate are acetylated and amidated variants with extended half-life); Selank, an anxiolytic heptapeptide modeled on tuftsin; dihexa; and Cerebrolysin, which is not a single peptide but a porcine-brain-derived peptide mixture administered by injection.
Because these compounds sit largely outside Western regulatory approval, users should understand three things before reading: the evidence base is heavily Russian-language and uneven in methodological quality; supply-chain reliability for research-chemical sources is poor and has worsened after 2025's enforcement actions; and clinical outcomes reported in case reports or user communities should not be interpreted as proof of efficacy. The guide presents what is known with appropriate caveats.
Nootropic Peptide Landscape: Mostly Russian-Origin, Limited Western Trials
The peptide nootropic landscape has a distinctive geographic pattern. Approved or widely marketed nootropic peptides in Russia include Semax (registered 1994 for stroke recovery, ischemic optic neuropathy, and cognitive impairment), Selank (registered 2004 for generalized anxiety disorder), Cortexin (a polypeptide mix from bovine cortex), and Cerebrolysin (a porcine-brain peptide hydrolysate, available in some European countries but not the US). None of these have FDA approval or ongoing US clinical development programs.
Several structural reasons contribute to this geographic concentration. Soviet and Russian neuropharmacology developed along distinct research traditions, with heavy investment in short-peptide regulators of brain function — a field that attracted less commercial interest in the West where receptor-targeted small molecules dominated. Clinical-trial quality in the Russian literature varies: some trials are well-designed RCTs meeting modern GCP standards, others are open-label observational studies with endpoints not mapped to Western neurology conventions.
The Western research-chemical ecosystem has absorbed many of these compounds, typically selling nasal sprays (Semax, Selank) and lyophilized powders for reconstitution (all of the above). Since the 2025 FDA enforcement wave and the shutdown of several major suppliers, supply has become less reliable and product-quality concerns — identity, purity, sterility — have increased. Users evaluating nootropic peptides should weigh the Russian clinical evidence on its merits while accounting for the meaningfully different regulatory frameworks and supply reliability in the West.
Semax Family: Parent Molecule, Semax 4-7, and N-Acetyl Variants
Semax is a 7-amino-acid synthetic peptide with sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to the 4-10 fragment of ACTH with a C-terminal Pro-Gly-Pro extension that confers metabolic stability. The peptide was developed at the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry in Moscow and the Institute of Molecular Genetics, registered as a nasal spray for neurological indications, and has accumulated a substantial Russian clinical literature in ischemic stroke (where it is given as adjunctive therapy in the first days after stroke onset) and cognitive impairment.
The mechanism involves BDNF upregulation, melanocortin receptor modulation (inherited from the ACTH lineage), and modulation of monoaminergic tone. Peripheral dosing (intranasal) achieves CNS penetration sufficient to produce measurable BDNF increases in animal models and EEG changes in humans.
Semax 4-7 is the C-terminal tetrapeptide fragment (Phe-Pro-Gly-Pro). Research with Semax 4-7 explored whether the minimal pharmacophore sufficed to reproduce parent-molecule effects; some studies suggested partial retention of neuroprotective activity with reduced HPA-axis engagement. Commercial supply of Semax 4-7 is less common than parent Semax.
N-acetyl-Semax is the N-terminally acetylated version of the parent peptide, and N-acetyl-Semax amidate (NA-Semax-amidate) adds a C-terminal amide. Both modifications resist aminopeptidase and carboxypeptidase degradation, extending the effective half-life relative to native Semax. In research-chemical communities these are the most widely used forms, typically dosed intranasally. No rigorous head-to-head comparison between the native and acetylated forms exists in peer-reviewed literature, but the rationale for acetylation is mechanically sound.
Selank: Anxiolytic Heptapeptide and GABA Modulation
Selank is a 7-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the immunomodulatory peptide tuftsin (the C-terminal Pro-Gly-Pro tail is again the stability modification). Developed at the Institute of Molecular Genetics in Moscow and registered in Russia in 2004 for generalized anxiety disorder, Selank is the anxiolytic counterpart to Semax's nootropic profile.
The proposed mechanism centers on GABA modulation without direct GABA-receptor binding. Selank has been shown in rodent models to alter expression of GABA-A receptor subunits, modulate serotonergic and monoaminergic tone, and affect the mRNA expression of anxiety- and stress-related genes in brain. Unlike benzodiazepines, Selank does not produce sedation, cognitive impairment, or dependence — the Russian clinical-trial literature specifically reports that Selank can be used without the tolerance and withdrawal issues characteristic of GABAergic sedatives. It also lacks the 4–6 week onset delay of SSRIs.
Dosing is typically intranasal, 75–150 μg per nostril up to several times daily. Clinical trials from the Moscow development group compared Selank favorably to medazepam (a benzodiazepine) in GAD patients, reporting comparable anxiolytic efficacy without the sedation and cognitive side effects. As with Semax, the evidence is almost entirely Russian, and no Western replication trial has been published.
Selank is frequently paired in research-chemical protocols with Semax or N-acetyl-Semax — the logic being anxiolytic balance to Semax's stimulating cognitive profile. This pairing is not a formal Russian clinical protocol but reflects popular self-experimentation patterns.
Dihexa: Hepatocyte Growth Factor Mimetic Hexapeptide
Dihexa is a 6-amino-acid peptide (N-hexanoic-Tyr-Ile-(6) amino-hexanoic-amide, also called PNB-0408) developed in the laboratory of Joseph Harding at Washington State University. Structurally derived from angiotensin IV — a neuropeptide generated from angiotensin II in brain — dihexa was engineered for oral bioavailability and brain penetration, resulting in a small peptide that behaves pharmacokinetically almost like a small molecule.
Mechanistically, dihexa is proposed to function as a hepatocyte growth factor (HGF) / c-Met receptor positive modulator. HGF is a potent neurotrophic factor implicated in synaptogenesis, neuronal survival, and synaptic plasticity, and the c-Met receptor is expressed throughout hippocampus and cortex. Dihexa augments HGF-c-Met signaling, reportedly stimulating dendritic spine density and improving performance on learning and memory tasks in aged and amyloid-burdened rodent models.
Preclinical publications in the 2010s generated significant interest in dihexa as an Alzheimer's-disease lead compound. However, no human clinical trials of dihexa have been published, and the peptide remains in the preclinical and research-chemical space. It is distinct from the Russian nootropic lineage in origin and mechanism but has been absorbed into the same self-experimentation ecosystem because of its neurotrophic mechanism and claims about cognitive effects.
Dihexa is sometimes described as 'peptide-like' or 'peptidomimetic' rather than a classical peptide. Its structure and oral bioavailability position it closer to small-molecule drugs in pharmacokinetics, while its mechanism places it in the neurotrophic-factor modulator class.
Cerebrolysin: Porcine Brain Peptide Hydrolysate (Not a Single Peptide)
Cerebrolysin is distinct from every other compound in this guide: it is not a single peptide but a complex mixture derived from enzymatic breakdown of young porcine brain tissue, consisting of low-molecular-weight peptides (under 10 kDa) and free amino acids. The manufacturer describes it as containing neurotrophic-like activity approximating that of endogenous growth factors, though the active components have not been fully characterized.
Cerebrolysin is administered by intravenous or intramuscular injection, typically 10–30 mL per session over 5–20 session courses. It is approved in roughly 40 countries, primarily in Eastern Europe, Russia, Asia, and Latin America, for ischemic stroke, traumatic brain injury, Alzheimer's disease, and vascular dementia. Several meta-analyses have pooled Cerebrolysin stroke-recovery trials and reported modest improvements in functional outcome at 90 days, though individual trial quality varies and the heterogeneity across studies is substantial.
The compound has not been approved by the FDA, and it does not circulate in the US research-chemical market in the same way Semax and Selank do, in part because the ampoule-and-IV administration format makes distribution harder. Western neurology has generally viewed Cerebrolysin with skepticism due to the difficulty of quality-controlling a complex biological extract and the challenge of interpreting the meta-analytic evidence.
Cerebrolysin is included in this guide because it is frequently discussed alongside Semax and Selank in nootropic and neurorehabilitation contexts, but its biology, mechanism, and regulatory status differ substantially from the single-peptide compounds that dominate the rest of the category.
Research Status: Why These Haven't Been Approved in the West
Several structural reasons explain the Western regulatory gap. FDA approval requires large, well-powered Phase III trials meeting specific primary-endpoint conventions; Russian registration historically accepted smaller and sometimes open-label trials. The cost of generating FDA-quality evidence for an already-generic peptide with no patent protection is prohibitive for most potential sponsors, and the original Russian developers have not partnered with Western pharma to fund such trials.
There are also pharmacologic challenges. Intranasal delivery, used for Semax and Selank, is difficult to standardize under FDA bioequivalence rules. Short peptides with multiple mechanistic actions (BDNF modulation plus melanocortin binding plus monoaminergic effects for Semax, for example) are harder to package as a single-target therapy than small-molecule SSRIs or benzodiazepines. Cerebrolysin's compositional heterogeneity essentially precludes conventional FDA approval without a complete re-characterization.
Finally, nootropic peptides occupy a difficult regulatory category: cognitive-enhancement claims in healthy users are not an FDA-approvable indication, and the mild-cognitive-impairment and early-Alzheimer's populations where these compounds might be studied are demanding trial populations with high failure rates. The commercial risk-adjusted return on a peptide already generic and available through compounding pharmacies and research-chemical channels is not attractive.
The practical takeaway for users: evidence for Semax in ischemic stroke and Selank in GAD is legitimate within the Russian clinical framework but not FDA-validated. Dihexa remains preclinical. Cerebrolysin has meta-analytic stroke data that is suggestive but not definitive. Responsible evaluation requires recognizing these compounds as promising but incompletely validated by Western standards rather than as established therapies.
Frequently asked questions
Full Semax is a 7-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) corresponding to ACTH 4-10 with a stabilizing Pro-Gly-Pro tail. Semax 4-7 is a shorter tetrapeptide fragment (Phe-Pro-Gly-Pro) representing just the C-terminal stabilizing portion. Research has explored whether this minimal pharmacophore retains neuroprotective effects with reduced HPA-axis engagement, though clinical data is limited and parent Semax dominates both clinical and research-chemical use.
N-acetyl-Semax adds an acetyl group to the N-terminus, which blocks aminopeptidase degradation and extends effective half-life. N-acetyl-Semax-amidate additionally adds a C-terminal amide, blocking carboxypeptidase degradation. These modifications produce longer-duration effects from a single intranasal dose. Research-chemical users frequently prefer the acetylated variants for dosing convenience, though head-to-head clinical comparisons against native Semax are scarce.
Dihexa sits at the boundary. Structurally it is a 6-amino-acid peptide derived from angiotensin IV with hexanoic acid modifications at both termini. Pharmacokinetically it behaves more like a small molecule — orally bioavailable, brain-penetrant, resistant to peptidase degradation. It is often described as peptidomimetic because its modifications take it outside the classical peptide pharmacokinetic profile while retaining the core peptide backbone.
Yes, extensively. Multiple trials and meta-analyses have evaluated Cerebrolysin in acute ischemic stroke, reporting modest improvements in 90-day functional outcomes in pooled analyses. Individual trial quality varies widely and heterogeneity across studies is substantial. It is approved for stroke in roughly 40 countries (Russia, parts of Europe and Asia) but not the FDA, and Western neurology views the evidence as suggestive but not definitive.
No. Semax, Selank, dihexa, and Cerebrolysin all lack FDA approval. They are sold in the US exclusively through research-chemical channels with no clinical-grade quality control. Semax and Selank have Russian regulatory approval dating to the 1990s and 2000s respectively; Cerebrolysin is approved in numerous countries but not the US; dihexa is entirely preclinical with no approved status anywhere as of early 2026.